means the drug is unlikely to reach GSK’s previous forecast sales of $1.6 billion by 2020. Developed with US respiratory specialist firm Innoviva, Relvar/Breo Ellipta recorded sales of £257 ...

Trelegy may well cannibalise sales of GSK's newer double therapy, Breo Ellipta, which is slowly gaining market share. The FDA has given Trelegy a licence for long-term, second line maintenance use ...

Teva Pharmaceutical Industries Ltd. ADR-0.28% $24.91B ...

After hours: 7:46:01 p.m. EST ...

incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 37,603.90 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

After hours: 7:55:12 pm GMT-5 ...

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...

After hours: December 31 at 4:08:27 PM EST Loading Chart for INVA ...

24 Jul, 2018 11 Sep, 2018 1:1 For every 1 share held; Holder will receive 1 bonus shares. 28 Sep, 1994 02 Jan, 1995 1:1 For every 1 share held; Holder will receive 1 bonus shares. 23 Jun, 1980-1:3 ...